Publication Cover
Endothelium
Journal of Endothelial Cell Research
Volume 14, 2007 - Issue 2
28
Views
17
CrossRef citations to date
0
Altmetric
Regular Articles

Zoledronate Inhibits αvβ3 and αvβ5 Integrin Cell Surface Expression in Endothelial Cells

, , &
Pages 123-130 | Received 11 Oct 2006, Accepted 25 Feb 2007, Published online: 13 Jul 2009
 

Abstract

Zoledronate exhibits antiangiogenic properties in vitro and in vivo. Integrins αvβ3 and αvβ5 are involved in angiogenesis. Because zoledronate inhibits endothelial cell adhesion, the authors explored the hypothesis that it could alter these integrins recruitment to focal adhesion sites. Human umbilical vein endothelial cells (HUVECs) were treated with zoledronate or with mevalonate pathway intermediates geranylgeraniol (GGOH) and farnesol (FOH). Zoledronate generated a significant decrease in αvβ3 and αvβ5 expression at HUVEC cell surface using flow cytometry and immunofluorescence. This inhibition was reversed by GGOH but not by FOH. Cells cotreated with zoledronate and GGOH were able to attach to vitronectin through αvβ3 and αvβ5, as confirmed by the use of specific function-blocking antibodies. The authors showed that zoledronate alters endothelial cell integrin-mediated adhesion. This effect is likely to contribute to the previously demonstrated antiangiogenic effect of zoledronate. Whether this mechanism of action also applies to metastatic tumor cells is under investigation.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.